Postpartum Depression Market to Witness Sustained Growth Through 2034, Driven by Rising Awareness, Early Diagnosis, and Expanding Therapeutic Pipeline | DelveInsight

Postpartum depression (PPD) is a severe, mood-related disorder that affects women following childbirth, characterized by persistent sadness, emotional detachment, fatigue, and anxiety. Unlike "baby blues," which are relatively common and transient, PPD can significantly impair a mother's ability to care for her newborn and herself. With symptoms often emerging within the first few weeks post-delivery-and sometimes even during pregnancy, PPD represents a critical, yet often underdiagnosed, facet of maternal mental health.

DelveInsight's latest report, "Postpartum Depression - Market Insight, Epidemiology, and Market Forecast - 2034," offers an in-depth analysis of the global postpartum depression landscape across key geographies, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The report provides insights into epidemiological trends, diagnostic practices, patient stratification, and current and emerging treatment paradigms shaping the market outlook.

Globally, postpartum depression affects approximately 10-15% of new mothers, with prevalence rates varying based on cultural, socioeconomic, and healthcare accessibility factors. The burden of PPD is being increasingly recognized due to rising awareness, improved screening protocols such as the Edinburgh Postnatal Depression Scale (EPDS), and broader societal acceptance of maternal mental health as a public health priority.

The postpartum depression market is expected to grow steadily through 2034, fueled by an expanding therapeutic pipeline, increased screening in obstetric settings, and healthcare policy initiatives aimed at integrating mental health support into routine maternal care. Pharmaceutical companies are actively developing novel mechanisms of action targeting GABA-A receptors and hormonal imbalances believed to be central to PPD pathophysiology.

With growing investments in women's health, a broader acceptance of mental health treatment, and the rise of digital therapeutics and telepsychiatry platforms, the future of postpartum depression care is poised to become more accessible, personalized, and stigma-free.

Request a sample and uncover the latest breakthroughs shaping the postpartum depression market landscape and future outlook @ https://www.delveinsight.com/report-store/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Postpartum Depression Market Report:
• The market size of postpartum depression in the 7MM was ~USD 260M in 2023.
• 1.3M diagnosed prevalent cases of PPD across the 7MM in 2023.
• ~460K female cases reported in EU4 and the UK in 2023.
• PPD is the most common non-psychotic complication after childbirth.
• Screening is typically done 2-6 months postpartum; assessment should include checking for manic symptoms.
• The Edinburgh Postnatal Depression Scale (EPDS) is a widely used screening tool.
• ZURZUVAE (oral, 50 mg for 14 days) and ZULRESSO (IV infusion) are the only approved treatments for PPD.
• In March 2025, Sooma Medical announced it received FDA Investigational Device Exemption (IDE) for its transcranial direct current stimulation (tDCS) device. This approval allows the company to begin a pivotal study of the device. Based in Helsinki, Finland, Sooma designed the tDCS device to treat depression through portable neuromodulation.
• In March 2025, PharmaTher Holdings Ltd. announced the resubmission of its response to the complete response amendment for its FDA new drug application for Ketamine, addressing the minor deficiencies outlined in the FDA's complete response letter (CRL) dated October 22, 2024.
• In January 2025, the FDA approved Johnson & Johnson's Spravato (esketamine) as the first and only standalone monotherapy for treatment-resistant depression (TRD).
• Emerging therapies for Postpartum Depression include GH001, RE-104, LPCN1154, BRII-297, and others.
• Key companies involved in the treatment of Postpartum Depression include GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, Sage Therapeutics, Biogen, Marinus Pharmaceuticals, and others.

Curious to know what's happening in the postpartum depression market? Get the latest insights right here: https://www.delveinsight.com/report-store/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Postpartum Depression Overview
Postpartum depression (PPD) is a complex and debilitating mood disorder that occurs in women after childbirth, typically within the first few weeks to months. Unlike the temporary "baby blues," PPD is more severe, lasting longer and often requiring medical intervention. Common symptoms include persistent sadness, fatigue, anxiety, irritability, sleep disturbances, and difficulty bonding with the newborn. While the exact cause is multifactorial, it is widely attributed to a combination of hormonal shifts, genetic predisposition, psychological stress, and environmental triggers. Women with a prior history of depression or anxiety, lack of social support, or complicated deliveries are at a heightened risk.

The global burden of postpartum depression is significant, with prevalence estimates ranging from 10-20% among new mothers. In the United States alone, hundreds of thousands of women are affected annually. Recent advances in neurobiology have led to the emergence of targeted therapies such as brexanolone (the first FDA-approved drug for PPD) and zuranolone, both of which modulate neuroactive steroids like allopregnanolone. As awareness grows and screening improves, the postpartum depression market is witnessing increasing interest in both pharmacological and non-pharmacological treatments, with a strong focus on early diagnosis, maternal well-being, and long-term infant outcomes.

Get a free sample for the postpartum depression market forecast, size & share analysis report: https://www.delveinsight.com/report-store/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Postpartum Depression Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.
Postpartum Depression Epidemiology Segmentation:

The Postpartum Depression market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Diagnosed Prevalent Population of Maternal Postpartum Depression

Postpartum Depression Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Postpartum Depression throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Postpartum Depression drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Postpartum Depression, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Postpartum Depression therapeutics.

Explore how emerging postpartum depression therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Postpartum Depression Market Outlook
Despite existing limitations in the current postpartum depression treatment market, the therapeutic landscape is poised for meaningful transformation. With several promising therapies in development, particularly those targeting novel mechanisms such as GABAA receptor positive allosteric modulators, the unmet need in treating PPD is gradually being addressed. Key pharmaceutical players like Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences are driving innovation in this space with a focus on improving efficacy and minimizing risks for both mothers and infants.

As these novel therapies move closer to regulatory approval, and with increasing awareness, early diagnosis, and rising healthcare investment across the 7MM (US, EU4, UK, and Japan), the postpartum depression market is expected to expand significantly between 2024 and 2034. The anticipated market growth will be fueled by improved treatment outcomes, greater access to care, and the availability of more personalized and safer therapeutic options for new mothers battling PPD.

Postpartum Depression Market Drivers
• The development of innovative drugs, such as GABAA receptor modulators (e.g., zuranolone), offers promising alternatives to traditional antidepressants. These treatments demonstrate rapid onset of action and better tolerability, which is crucial in addressing the acute needs of postpartum patients, driving growth in the postpartum depression treatment market.
• Increased awareness of maternal mental health, better screening protocols, and reduced stigma surrounding postpartum mental disorders are leading to earlier diagnosis and timely treatment. This trend is expanding the treated population, fueling demand in the PPD market across developed and emerging healthcare systems.

Postpartum Depression Market Barriers
• A major limitation in PPD therapy is the concern over the safety of medications for breastfeeding infants. Many antidepressants, though effective, pose potential risks of adverse neonatal effects, leading to hesitation among physicians and patients and contributing to under-treatment.
• Despite a high prevalence, there are very few drugs approved specifically for postpartum depression. Most current options are off-label uses of general antidepressants, which may not adequately address the unique biological and psychological features of PPD, creating a therapeutic gap and slowing market expansion.

Scope of the Postpartum Depression Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Postpartum Depression Companies: GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, Sage Therapeutics, Biogen, Marinus Pharmaceuticals, and others.
• Key Postpartum Depression Therapies: GH001, RE-104, LPCN1154, BRII-297, and others.
• Postpartum Depression Therapeutic Assessment: Postpartum Depression currently marketed, and Postpartum Depression emerging therapies.
• Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Postpartum Depression Unmet Needs, KOL's views, Analyst's views, Postpartum Depression Market Access and Reimbursement.

To learn more about postpartum depression companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Postpartum Depression Market Report Introduction
2. Executive Summary for Postpartum Depression
3. SWOT analysis of Postpartum Depression
4. Postpartum Depression Patient Share (%) Overview at a Glance
5. Postpartum Depression Market Overview at a Glance
6. Postpartum Depression Disease Background and Overview
7. Postpartum Depression Epidemiology and Patient Population
8. Country-Specific Patient Population of Postpartum Depression
9. Postpartum Depression Current Treatment and Medical Practices
10. Postpartum Depression Unmet Needs
11. Postpartum Depression Emerging Therapies
12. Postpartum Depression Market Outlook
13. Country-Wise Postpartum Depression Market Analysis (2020-2034)
14. Postpartum Depression Market Access and Reimbursement of Therapies
15. Postpartum Depression Market Drivers
16. Postpartum Depression Market Barriers
17. Postpartum Depression Appendix
18. Postpartum Depression Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.